AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30

AYTU BIOPHARMA, INC

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026

$1.96−0.08 (-3.92%)

Close on Oct 19, 2026

Community

Notes and questions about Aytu Biopharma from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Aytu Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Jan 6, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AYTU.

Revenue growth-13.3% · median 20.9%

Gross margin64.0% · median 87.1%

Operating margin-14.4% · median -86.1%

Net margin-24.8% · median -127.4%

Advertisement
300 × 250